These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 8093726)

  • 1. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1387-91. PubMed ID: 8099621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
    Boldry RC; Chase TN; Engber TM
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1454-9. PubMed ID: 7903390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Ni L
    J Pharmacol Exp Ther; 1998 Jan; 284(1):307-11. PubMed ID: 9435192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
    Campbell BM; Kreipke CW; Walker PD
    Neuroscience; 2006; 137(2):505-17. PubMed ID: 16289829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P; Bédard PJ; Britton DR; Kebabian JW
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV; Groenewegen HJ; Voorn P
    Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
    Schmidt HD; Pierce RC
    Neuroscience; 2006 Oct; 142(2):451-61. PubMed ID: 16844308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
    Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
    J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
    Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys.
    Gasior M; Paronis CA; Bergman J
    J Pharmacol Exp Ther; 2004 Jan; 308(1):249-59. PubMed ID: 14563783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
    Domino EF; Ni L
    Eur J Pharmacol; 2008 Dec; 599(1-3):81-5. PubMed ID: 18851961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
    Jutkiewicz EM; Bergman J
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M; Fukuda T
    Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
    [No Abstract]   [Full Text] [Related]  

  • 17. Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys.
    Rowlett JK; Platt DM; Yao WD; Spealman RD
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1135-43. PubMed ID: 17351103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
    Criswell HE; Johnson KB; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
    Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
    Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.